Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

Abstract excerpt

During the last two decades, kinase inhibitors have become the major drug class for targeted cancer therapy. Although the number of approved kinase inhibitors increases rapidly, comprehensive in vitro profiling and comparison of inhibitor activities is often lacking in the public domain. Here we report the extensive profiling and comparison of 21 kinase inhibitors approved by the FDA for oncology indications...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Fibroblast Growth Factor Research
• Share to Lung Cancer Treatments and Mutations
• Share to PI3K/AKT/mTOR signaling in cancer